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Abstract 
Renal failure after left ventricular assist device (LVAD) implantation occurs either 
due to worsening chronic kidney disease which is common in end-stage heart 
failure, or due to acute kidney injury in the peri-implantation period, and is 
associated with high morbidity and shortterm mortality. The increased utilization 
of LVAD in refractory heart failure either as a bridge to transplantation or 
destination therapy will eventually create a population of patients with LVADs 
who are dialysis-dependent. There are multiple challenges encountered during 
dialysis of patients with LVADs including the unfamiliarity of nephrologists with 
the LVAD technology, difficulty in hemodynamic monitoring with continuous flow 
devices, risk of access site infection or bleeding and poor arteriovenous fistula 
maturation and these reasons are the source for the reluctance of outpatient 
dialysis centers to accept such cases. The nephrologists as well as cardiologists 
should be familiar with these obstacles to avoid adverse consequences to these 
high risk patients. Herein, we explore the challenges encountered during dialysis 
of patients with LVADs. 
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Introduction 
Left ventricular assist devices (LVADs) have become an integral tool in the 
treatment of patients with refractory heart failure either as a bridge to 
transplantation or as destination therapy (DT) in those who are not candidates for 
heart transplantation (HT) [1, 2] as it decrease morbidity, improve the quality of 
life [3] and prolong survival [4]. According to the INTERMACS registry, more than 
10000 LVADs have been implanted since 2006 in yearly increasing increments 
with nearly 2500 LVADs implanted in 2013 [5]. This continued rise in LVAD 
placement will generate a population of patients with LVAD-related complications 
including the requirement for long term renal replacement therapy (RRT). Acute 
renal failure after LVAD implantation is mainly related to irreversible kidney injury 
occurring in the peri-implantation period [6, 7] especially in the setting of chronic 
kidney disease which is common in up to 45% of patients with ambulatory heart 
failure [8] and 64% of patients hospitalized with decompensated heart failure [9]. 
LVAD recipients who require RRT post implantation have unfavorable outcomes 
due to the high morbidity and short-term mortality [7, 10] especially in those not 
bridged to HT. The mortality of LVAD patients who develop postoperative acute 
kidney injury has been estimated at approximately 57% to 93% in prior studies 
[11- 16].  
The International Society for Heart and Lung Transplantation (ISHLT) guidelines 
for mechanical circulatory support have thus recommended that the requirement 
for permanent RRT is a contraindication for LVAD implantation as a DT [17] but 
is not a contraindication in those receiving LVAD as a bridge to HT. The technical 
problems faced by nephrologists and dialysis centers managing patients with 
LVADs requiring RRT include: unfeasibility of hemodynamic monitoring in 
patients without a pulse, risk of drive line infection through dialysis catheters, and 
anticoagulant management and risk of bleeding. This has resulted in the 
reluctance of outpatient dialysis centers to accept patients with LVADs and 
therefore they may remain hospitalized leading to prolonged hospital stay which 
is detrimental to the patients’ quality of life [18]. This warrants a close 
collaboration between the cardiologist and nephrologist to ensure a smooth 
transition of patients with LVADs requiring RRT from inpatient to outpatient 
dialysis. Herein, we aim to review the various obstacles facing the nephrologists 
and dialysis centers treating patients with LVADs requiring RRT. 
Hemodialysis access challenges and concerns regarding 
arteriovenous fistula maturation 
Hemodialysis access is a main challenge for patients with LVADs requiring RRT. 
These patients typically do not already have arteriovenous (AV) fistula or graft 
because they are not dialysis dependent pre-implant and RRT is usually started 
post LVAD placement. In the general dialysis population, AV fistula is known to 
be the optimal hemodialysis access as it is associated with prolonged survival, 
lower risk of infection, lesser hospitalization rates and reduced cost [19]. 
Nonetheless, there are concerns for poor AV fistula maturation in patients with 
LVAD due to lack of vascular reactivity as a result of the nonpulsatile blood flow 
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nonpulsatile blood flow is associated with decreased flow-mediated vasodilation 
[21]. It is recommended to maintain the mean arterial pressure in the range of 70 
to 80 mmHg and not to exceed 90 mmHg in LVAD patients, as high afterload my 
compromise unloading of the left ventricle [22]. Also, the patient’s low blood 
pressure after LVAD implantation may be a risk of access thrombosis.  
Thrombosis of AV fistula due to low blood pressure may happen even in the 
absence of anatomical lesions [23]. Sasson and colleagues reported that 
spontaneous AV fistula maturation has not occurred in any of the patients with 
LVAD at their institution but suggested the option of assisted AV fistula 
maturation [24]. They have reported two cases demonstrating the assisted 
maturation of AV fistula for long term fistula patency (cumulative patency 329 
days and 511 days in the two presented patients) [24]. However, there are no 
formal studies examining the AV fistula in LVAD patients [25]. Because of these 
concerns with AV fistula, Patel and colleagues have recommended the use of AV 
graft as the preferred long term hemodialysis access [25].   
Dialysis access-related infection 
The risk of access-related blood stream and drive line infection is another 
challenge in patients with LVAD requiring RRT. Patients with LVAD are already 
at risk for infection that may be introduced through the lead electrode in the skin 
[20]. LVAD driveline exit site infection and subsequent bacteremia can spread to 
the LVAD itself and is a common cause of morbidity and mortality [26]. Topkara 
and colleagues showed that patients with LVAD requiring postoperative 
hemodialysis had a higher rate of sepsis and shorter post-LVAD survival [15].  
Argenziano and colleagues demonstrated that the occurrence of endocarditis in 
patients post LVAD implantation portended a poor prognosis [27]. In the general 
dialysis population, infectious complications are the second major cause of death 
only after cardiovascular disease [28, 29]. Because infection is found to be a 
leading cause of death in the peri-implant period, it has warranted a change in 
status to “urgent” for patients with LAVD awaiting HT [30].  
Dialysis access is an important source of infection in patients with LVAD 
requiring RRT. Several studies investigated the relationship between dialysis 
access type and subsequent infection risk [28, 29, 31-34]. The incidence of 
bacteremia was highest with temporary dialysis catheters and the second highest 
was tunneled cuffed dialysis catheters compared with AV grafts and AV fistulas 
[31, 32]. The risk of bacteremia was significantly reduced in the peritoneal 
dialysis population [31]. Moreover, peritoneal dialysis catheter-related peritonitis 
seldom leads to bacteremia [35]. The LVAD driveline is placed in the 
retroperitoneal space and the peritoneum is not entered. It was therefore 
suggested that peritoneal dialysis may pose a lower risk of systemic infection 
compared with hemodialysis in patients with LVAD and may theoretically reduce 
their morbidity and mortality [36]. 
Hemodialysis versus peritoneal dialysis 
There is lack of comparative trials to identify superiority of hemodialysis versus 
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suggested a probable favorable outcome for peritoneal dialysis for several 
reasons [35, 36]. Most importantly is the lower risk of infectious complications: a 
main cause of morbidity and mortality in patients with LVAD. Peritoneal dialysis 
catheters can be placed with conscious sedation and local anesthetic allowing 
dialysis to be started immediately [35]. It also allows the patient to perform 
dialysis at home –and thus decrease hospitalization costs- unlike patients on 
hemodialysis who usually end up having dialysis in the hospital because many 
dialysis centers do not accept LVAD cases owing to their unstable 
hemodynamics and the perceived difficulty in measuring the blood pressure.  
Sustained daily ultrafilteration with peritoneal dialysis offers more hemodynamic 
stability [36]. Peritoneal dialysis is known to be 25% less costly than 
hemodialysis [37]. Peritoneal dialysis also preserves residual renal functions 
compared to hemodialysis and therefore there is a higher chance of renal 
recovery [38] in those with viable renal parenchyma [35]. On the other hand, 
peritoneal dialysis may impede nutritional recovery in patients with LVAD who 
are usually malnourished [39]. In addition, some patients may have LVAD placed 
in the preperitoneal space which may pose challenges to safely conducting 
peritoneal dialysis [39]. Precise volume removal is also difficult with peritoneal 
dialysis compared to hemodialysis. Peritoneal dialysis may cause worsening of 
diabetes mellitus control due to the continuous glucose absorption from glucose-
containing peritoneal dialysis solutions [40].  
Concerns with hemodialysis in patients with LVAD include the fixed speed 
settings of continuous flow pumps. Most LVADs will not automatically adjust 
speed to cope with volume shifts and reduced preload which is a common 
hallmark during hemodialysis [36]. The temporary decrease of speed in some 
pumps in settings of reduced preload may also be insufficient to prevent hazards 
of volume shifts [36]. So far, the ideal dialysis technique in patients with LVAD is 
still debatable. Randomized controlled trials are mandatory to compare the 
outcome of peritoneal dialysis and hemodialysis in subjects with LVAD requiring 
RRT. 
Intradialytic blood pressure monitoring in patients with LVAD  
Hypotension is estimated to occur in 15 to 30% of the general hemodialysis 
population [41] and can reach up to 50% in high risk patients and those with 
LVADs [39, 42] and therefore blood pressure monitoring is crucial. Continuous-
flow LVADs offer several advantages over the older version pulsatile devices, 
such as smaller size, better durability and long-term outcomes [43, 44]. 
Unfortunately, the resultant continuous unloading of the left ventricle during the 
whole cardiac cycle causes diminished or absent pulse pressure [45]. Therefore 
the standard method of auscultation of the blood pressure is usually unfeasible 
unless a pulse pressure is present from residual ventricular function [25]. A 
significantly lower systolic, diastolic and mean arterial blood pressure is obtained 
with automated blood pressure devices compared with intra-arterial blood 
pressure recording and its success rate in continuous-flow -LVAD patients is only 
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Doppler ultrasonography has proven excellent success rates (~95%) with high 
validity and reliability and is considered the gold standard in measuring blood 
pressure in subjects with continuous-flow LVADs [39, 46, 47]. However, there is 
some controversy regarding whether the initial audible sound with Doppler 
ultrasonography represent the systolic blood pressure or the mean arterial 
pressure [46-48]. Studies showed that in patients with high pulse pressure, the 
initial audible sound with the Doppler technique is closer to the systolic blood 
pressure [47], while in cases with low pulse pressure, the initial Doppler sound is 
closer to the mean arterial pressure. Lanier and colleagues demonstrated a 90% 
success rate in measuring systolic blood pressure and mean arterial pressure 
using an automated Terumo Elemano blood pressure monitor (Somerset, NJ) 
which uses a double-cuff oscillometric slow deflation technology designed to 
improve sensitivity of blood pressure readings [47]. One should attempt 
validation of blood pressure devices against arterial line and/or Doppler 
recordings prior to its utilization in patients with continuous-flow LVAD [47]. 
Other concerns in patients with LVAD on chronic hemodialysis 
Patients with post LVAD acute kidney injury requiring RRT will need a 
hemodialysis catheter insertion. A concern in this instance is the risk of bleeding 
since anticoagulant therapy is crucial in all patients with LVADs to avoid 
thrombotic complications. Most of these patients are on various combinations of 
heparin, warfarin, aspirin and dipyridamole to decrease the risk of pump 
thrombosis and ischemic stroke [22, 49]. The operator should therefore be 
prepared to place the hemodialysis catheter in a patient with therapeutic level 
anticoagulation and to ensure adequate hemostasis of the chest tunnel in case of 
tunneled catheter placement [50].  
Anticoagulation also represents a risk for blood loss from an AV fistula during 
cannulation and this is compounded by uremic platelet dysfunction in chronic 
kidney disease. Dialysis catheter insertion should preferably be performed in a 
procedure room rather than bedside for better sterilization. Femoral access in 
obese patients who are at increased risk of infection should be avoided [50]. It is 
advised that the nephrologist does not adjust or reverse anticoagulant 
medications without consulting with the cardiac team [50]. A tunneled dialysis 
catheter is preferred over non-tunneled ones because of lower risk of infection. It 
is also advised that before starting any procedure to make sure that the batteries 
will cover the expected procedure duration, to have charged spare batteries 
available and to preferably have a technician specialized in LVAD management 
on standby till completion of the procedure [50]. There are also concerns that the 
placement of an AV fistula or AV graft may worsen heart failure (high cardiac 
output failure) in this subset of patients [50].  
Unanswered questions regarding the decision of LVAD placement in 
patients with non-dialysis dependent renal insufficiency and dialysis 
dependent patients  
Renal insufficiency is a comorbidity associated with early mortality in patients 
with end-stage heart failure on the waitlist for HT [51], and this include subjects 
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In patients with end-stage heart failure who are candidates for heart transplant, 
dialysis dependence is considered an indication for combined heart–kidney 
transplantation due to the improved five-year post-transplant survival in HKT 
recipients compared with isolated HT recipients for both dialysis dependent 
patients (73% vs. 51%, p < 0.001) and non-dialysis dependent patients (80% vs. 
69%, p < 0.001) [52]. The guidelines are too strict for end-stage heart failure 
patients with renal failure who are not candidates for HT. Because non-dialysis 
dependent renal insufficiency and hemodialysis at the time of LVAD implant are 
strong predictor for adverse outcomes [10], the ISHLT recommends that the 
need for permanent RRT is a contraindication for LVAD implantation as a DT 
(class III, level of evidence C) [17] but it is not a contraindication for those who 
will receive LVAD as a bridge to HT.  
An important question is whether patients with non-dialysis dependent renal 
insufficiency or those who are dialysis dependent would benefit from LVAD as 
DT? Although this is considered a class III indication for LVAD placement, there 
are few reports of patients with non-dialysis dependent renal insufficiency who 
required dialysis in the peri-implantation period and could be weaned off RRT 
[53] and other patients who received LVAD as DT and became dialysis 
dependent post-implant and then had uneventful chronic dialysis [54]. LVAD 
placement may be the only hope for this subset of patients who are not 
transplant candidates and need LVAD as DT.  
Previous studies have demonstrated improvement in renal function following 
LVAD implantation [55], but again this is difficult to predict [56]. Data by Levin 
and colleagues showed a favorable outcome in dialysis dependent patients 
receiving an LVAD as a bridge to transplantation [57]. They studied the outcomes 
of 35 patients on hemodialysis and 68 not on hemodialysis who received long 
term LVADs and found no significant difference in 1-year survival (73.3% 84.6% 
in dialysis and non-dialysis dependent patients, respectively, P=0.183) [57]. 
These encouraging results should promote further studies to determine the value 
of LVAD as DT in patients with dialysis dependent end-stage heart failure or non-
dialysis dependent renal insufficiency who are otherwise good candidates for DT.  
Another unanswered question is whether a patient with non-dialysis dependent 
renal insufficiency, should receive HT (followed by a staged kidney transplant in 
those without renal recovery) as opposed to HKT. It is possible that some 
patients may experience improvement in renal function with HT alone. Also 
whether patients with LVAD who remain dialysis dependent after implant would 
benefit more from renal transplantation alone? Till now, LVAD patients have not 
been considered for non-cardiac transplantation because the risk of driveline 
infection in an immunocompromised patient is a major concern [53].  
In conclusion, the yearly incremental increase in LVAD implantation caused a 
subsequent rise in the number of patients with LVAD who developed renal 
failure, some of which are dialysis dependent. The dialysis of these patients is 
challenging due to multiple factors including the reluctance of outpatient dialysis 
centers to accept these patient, unfamiliarity of nephrologists with LVADs, 
difficulty in hemodynamic monitoring during dialysis, risk of access site infection 
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for these patients (continuous venovenous hemodialysis vs. intermittent 
hemodialysis vs. peritoneal dialysis) needs further studies. Cardiologists and 
nephrologists involved in the care of patients with LVAD should be familiar with 
the physiologic and technologic aspects of these devices as well as obstacles 
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